A Nature Communications study led by Pagès-Geli, Ribeiro, Wienclaw and colleagues reports a high-throughput approach to engineer bispecific antibodies designed to boost macrophage killing of malignant B cells. The work focuses on improving the immune synapse between engineered antibody formats and macrophage effector functions, aiming to increase the probability that targeted B-cell lymphoma cells are eliminated.